Published in Arch Neurol on July 01, 2001
Modifier genes for hypertrophic cardiomyopathy. Curr Opin Cardiol (2002) 1.47
Genetic determinants of cardiac hypertrophy. Curr Opin Cardiol (2008) 1.35
Molecular genetics and pathogenesis of hypertrophic cardiomyopathy. Minerva Med (2001) 1.00
Hypoparathyroidism mimicking ankylosing spondylitis and myopathy: a case report. Clinics (Sao Paulo) (2011) 0.99
Rapid development of life-threatening complete atrioventricular block in Kearns-Sayre syndrome. Eur J Pediatr (2008) 0.88
Hypoparathyroidism as the first manifestation of kearns-sayre syndrome: a case report. Iran J Child Neurol (2013) 0.75
Causes of Death in Adults with Mitochondrial Disease. JIMD Rep (2015) 0.75
An unstable triplet repeat in a gene related to myotonic muscular dystrophy. Science (1992) 8.20
International Cooperative Ataxia Rating Scale for pharmacological assessment of the cerebellar syndrome. The Ataxia Neuropharmacology Committee of the World Federation of Neurology. J Neurol Sci (1997) 4.50
Mutations in Kir2.1 cause the developmental and episodic electrical phenotypes of Andersen's syndrome. Cell (2001) 4.25
Autosomal dominant cerebellar ataxia (SCA6) associated with small polyglutamine expansions in the alpha 1A-voltage-dependent calcium channel. Nat Genet (1997) 4.12
Intranuclear inclusions of expanded polyglutamine protein in spinocerebellar ataxia type 3. Neuron (1997) 3.73
CAG repeat expansion in Huntington disease determines age at onset in a fully dominant fashion. Neurology (2012) 3.12
Decreased expression of myotonin-protein kinase messenger RNA and protein in adult form of myotonic dystrophy. Science (1993) 2.75
Clinical evaluation of idiopathic paroxysmal kinesigenic dyskinesia: new diagnostic criteria. Neurology (2004) 2.70
RNA CUG repeats sequester CUGBP1 and alter protein levels and activity of CUGBP1. J Biol Chem (2000) 2.65
Large expansion of the ATTCT pentanucleotide repeat in spinocerebellar ataxia type 10. Nat Genet (2000) 2.60
Paroxysmal kinesigenic dyskinesia and infantile convulsions: clinical and linkage studies. Neurology (2000) 2.48
The GAA triplet-repeat expansion in Friedreich ataxia interferes with transcription and may be associated with an unusual DNA structure. Am J Hum Genet (1998) 2.39
RAN proteins and RNA foci from antisense transcripts in C9ORF72 ALS and frontotemporal dementia. Proc Natl Acad Sci U S A (2013) 2.31
Subcutaneous IGF-1 is not beneficial in 2-year ALS trial. Neurology (2008) 2.17
Measuring Friedreich ataxia: complementary features of examination and performance measures. Neurology (2006) 2.17
Measuring Friedreich ataxia: Interrater reliability of a neurologic rating scale. Neurology (2005) 1.79
Somatic mosaicism, germline expansions, germline reversions and intergenerational reductions in myotonic dystrophy males: small pool PCR analyses. Hum Mol Genet (1995) 1.74
Effect of myotonic dystrophy trinucleotide repeat expansion on DMPK transcription and processing. Genomics (1995) 1.74
Clinical and genetic analysis of four Mexican families with spinocerebellar ataxia type 10. Ann Neurol (2001) 1.74
Somatic heterogeneity of the CTG repeat in myotonic dystrophy is age and size dependent. Am J Hum Genet (1995) 1.62
Huntington's disease--like 2 can present as chorea-acanthocytosis. Neurology (2003) 1.57
Ethnic distribution of myotonic dystrophy gene. Lancet (1991) 1.54
Gametic and somatic tissue-specific heterogeneity of the expanded SCA1 CAG repeat in spinocerebellar ataxia type 1. Nat Genet (1995) 1.51
A novel X-linked gene, DDP, shows mutations in families with deafness (DFN-1), dystonia, mental deficiency and blindness. Nat Genet (1996) 1.45
Clinical phenotype of Brazilian families with spinocerebellar ataxia 10. Neurology (2004) 1.40
Molecular and clinical correlations in spinocerebellar ataxia type I: evidence for familial effects on the age at onset. Am J Hum Genet (1994) 1.38
New NBIA subtype: genetic, clinical, pathologic, and radiographic features of MPAN. Neurology (2012) 1.35
Induction of mammalian DNA topoisomerase I mediated DNA cleavage by antitumor indolocarbazole derivatives. Biochemistry (1992) 1.33
Measuring the rate of progression in Friedreich ataxia: implications for clinical trial design. Mov Disord (2010) 1.29
Atypical Friedreich ataxia caused by compound heterozygosity for a novel missense mutation and the GAA triplet-repeat expansion. Am J Hum Genet (1997) 1.27
Novel mutations in collagen VI genes: expansion of the Bethlem myopathy phenotype. Neurology (2002) 1.20
The role of ataxin 10 in the pathogenesis of spinocerebellar ataxia type 10. Neurology (2006) 1.20
Cardiac involvement in a large kindred with myotonic dystrophy. Quantitative assessment and relation to size of CTG repeat expansion. JAMA (1995) 1.17
A novel ryanodine receptor gene mutation causing both cores and rods in congenital myopathy. Neurology (2000) 1.16
Clinical characteristics of patients with spinocerebellar ataxias 1, 2, 3 and 6 in the US; a prospective observational study. Orphanet J Rare Dis (2013) 1.15
Molecular and clinical correlations in spinocerebellar ataxia type 3 and Machado-Joseph disease. Ann Neurol (1995) 1.15
Variability and validity of polymorphism association studies in Parkinson's disease. Neurology (2000) 1.14
Interactions between coilin and PIASy partially link Cajal bodies to PML bodies. J Cell Sci (2005) 1.13
Molecular and clinical studies in SCA-7 define a broad clinical spectrum and the infantile phenotype. Neurology (1998) 1.13
Cerebral vasculitis in relapsing polychondritis. Neurology (1988) 1.11
Mapping of the gene for a novel spinocerebellar ataxia with pure cerebellar signs and epilepsy. Ann Neurol (1999) 1.11
Length-dependent structure formation in Friedreich ataxia (GAA)n*(TTC)n repeats at neutral pH. Nucleic Acids Res (2004) 1.09
Association of homozygous 7048G7049 variant in the intron six of Nurr1 gene with Parkinson's disease. Neurology (2002) 1.08
Tick paralysis. Semin Neurol (2004) 1.08
"Orthostatic tremor' in familial-essential tremor. Neurology (1986) 1.07
"Mitotic drive" of expanded CTG repeats in myotonic dystrophy type 1 (DM1). Hum Mol Genet (2001) 1.06
CINRG randomized controlled trial of creatine and glutamine in Duchenne muscular dystrophy. Ann Neurol (2005) 1.04
Consensus paper: pathological mechanisms underlying neurodegeneration in spinocerebellar ataxias. Cerebellum (2014) 1.03
De novo myotonic dystrophy mutation in a Nigerian kindred. Am J Hum Genet (1995) 1.00
Ethnic origin and extrapyramidal signs in an Argentinean spinocerebellar ataxia type 10 family. Neurology (2007) 0.99
Rational selection of small molecules that increase transcription through the GAA repeats found in Friedreich's ataxia. FEBS Lett (2006) 0.99
Pi35(t), a new gene conferring partial resistance to leaf blast in the rice cultivar Hokkai 188. Theor Appl Genet (2006) 0.98
Spinocerebellar ataxia type 10 is rare in populations other than Mexicans. Neurology (2002) 0.97
Reduced immunoreactivity to calcium-binding proteins in Purkinje cells precedes onset of ataxia in spinocerebellar ataxia-1 transgenic mice. Neurology (1998) 0.97
Polymorphism of NACP-Rep1 in Parkinson's disease: an etiologic link with essential tremor? Neurology (2000) 0.97
Disruption of the purine nucleotide cycle. A potential explanation for muscle dysfunction in myoadenylate deaminase deficiency. J Clin Invest (1980) 0.97
Calcium homeostasis and spinocerebellar ataxia-1 (SCA-1). Brain Res Bull (2001) 0.97
Generation of human-induced pluripotent stem cells to model spinocerebellar ataxia type 2 in vitro. J Mol Neurosci (2012) 0.96
False positive anti-acetylcholine receptor antibodies in motorneurone disease. Lancet (1986) 0.95
Genetic testing in spinocerebellar ataxias: defining a clinical role. Arch Neurol (2001) 0.95
Very large (CAG)(n) DNA repeat expansions in the sperm of two spinocerebellar ataxia type 7 males. Hum Mol Genet (1999) 0.95
Orthotopic liver transplantation for biliary atresia. Evolution of management. Arch Surg (1988) 0.94
Germline mutational dynamics in myotonic dystrophy type 1 males: allele length and age effects. Neurology (2004) 0.94
Tourettism associated with Huntington's disease. Mov Disord (1995) 0.94
Long-term safety of dichloroacetate in congenital lactic acidosis. Mol Genet Metab (2013) 0.93
Antitumor quinolones with mammalian topoisomerase II mediated DNA cleavage activity. Cancer Res (1992) 0.93
Genetic and physical mapping of the partial resistance gene, pi34, to blast in rice. Phytopathology (2007) 0.92
Intranasal administration of IGF-I improves behavior and Purkinje cell pathology in SCA1 mice. Brain Res Bull (2006) 0.92
Myotonic dystrophy as a brain disorder. Arch Neurol (1998) 0.91
Lupus transverse myelopathy: better outcome with early recognition and aggressive high-dose intravenous corticosteroid pulse treatment. J Neurol (1995) 0.90
Clinical features of Todd's post-epileptic paralysis. J Neurol Neurosurg Psychiatry (1992) 0.90
Relationship between ataxin-1 nuclear inclusions and Purkinje cell specific proteins in SCA-1 transgenic mice. J Neurol Sci (2000) 0.90
Mutation in the kv3.3 voltage-gated potassium channel causing spinocerebellar ataxia 13 disrupts sound-localization mechanisms. PLoS One (2013) 0.90
Symptom onset of spinocerebellar ataxia type 10 in pregnancy and puerperium. J Clin Neurosci (2011) 0.90
Diabetic proximal neuropathy. Clinical and electromyographic studies. J Neurol Sci (1982) 0.89
Friedreich ataxia clinical outcome measures: natural history evaluation in 410 participants. J Child Neurol (2012) 0.89
Reduced penetrance of intermediate size alleles in spinocerebellar ataxia type 10. Neurology (2006) 0.88
Health related quality of life measures in Friedreich Ataxia. J Neurol Sci (2008) 0.87
A "dystrophic" variant of autosomal recessive myotonia congenita caused by novel mutations in the CLCN1 gene. Neurology (2000) 0.87
Randomized prospective trial of OKT3 for early prophylaxis of rejection after liver transplantation. Transplantation (1989) 0.87
NcoI and TaqI RFLPs for human M creatine kinase (CKM) Nucleic Acids Res (1988) 0.87
Functioning adrenocortical oncocytoma: the first documented case producing interleukin-6 and review of the literature. J Endocrinol Invest (2008) 0.86
An interrupted 34-CAG repeat SCA-2 allele in patients with sporadic spinocerebellar ataxia. Neurology (2000) 0.86
Paroxysmal kinesigenic dyskinesia and infantile convulsions. Clinical and linkage studies. 2000. Neurology (2001) 0.85
Lack of cold sensitivity in hyperkalemic periodic paralysis. Muscle Nerve (1986) 0.85
Generalized myokymia and gold therapy. Arch Neurol (1982) 0.85
Bergmann glial S100B activates myo-inositol monophosphatase 1 and Co-localizes to purkinje cell vacuoles in SCA1 transgenic mice. Cerebellum (2009) 0.85
SCA10 and ATTCT repeat expansion: clinical features and molecular aspects. Cytogenet Genome Res (2003) 0.85
A dominantly inherited syndrome with continuous motor neuron discharges. Ann Neurol (1983) 0.85
Immunohistochemical and molecular analysis of giant cell carcinoma of the pancreas: a report of three cases. Pancreas (1999) 0.85
Sequence variation in GAA repeat expansions may cause differential phenotype display in Friedreich's ataxia. Mov Disord (2001) 0.84
Role of central ATP-sensitive potassium channels in the analgesic effect and spinal noradrenaline turnover-enhancing effect of intracerebroventricularly injected morphine in mice. Brain Res (1992) 0.84
Synthesis and antitumor activity of novel thioester derivatives of leinamycin. J Med Chem (1999) 0.84
Steady or not following thalamic deep brain stimulation for essential tremor. J Neurol (2011) 0.83
Analysis of the visual system in Friedreich ataxia. J Neurol (2013) 0.83
Pharmacokinetic differences between morning and evening administration of cyclosporine and tacrolimus therapy. Transplant Proc (2005) 0.83
Generation of neural cells from DM1 induced pluripotent stem cells as cellular model for the study of central nervous system neuropathogenesis. Cell Reprogram (2013) 0.82